Therapies
The Science
About us
Investors
News

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016 Kerry Rowe

Abstract from Movement Disorders Conference 2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Prana receives $3 million R&D Tax Incentive Refund

December 19, 2017

Prana drug treatment PBT2 named one of Top Neuroscience Projects to Watch

September 4, 2013

Prana Biotechnology Presents to US Investors at 34th Cowen Healthcare Conference

March 4, 2014

Recent Posts

Chairman’s Address to Shareholders 2019 Annual General Meeting
AGM 2019 Presentation
Alterity AGM Investor Conference Call
Alterity’s lead drug candidate receives positive opinion from European medical agency
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065